Molecular Prognostic Testing and Individualized Patient Care in Uveal Melanoma

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Purpose: To critically assess the status of molecular prognostic testing and its use for individualized patient care in uveal melanoma. Design: Perspective, literature review, evidence assessment, and commentary. Methods: Evaluation of selected articles from the literature and the authors' clinical and laboratory studies. Results: The most accurate molecular tests for predicting metastatic death in patients with uveal melanoma currently involve automated techniques for assessing deoxyribonucleic acid (DNA) copy number alterations and gene expression profiling. Most tests reported in the literature to date do not provide adequate scientific and statistical validation to be used outside of an ethically supervised investigational environment. Conclusions: Many cytogenetic and molecular prognostic tests for uveal melanoma have been reported, yet few have reached the standards required for routine clinical testing. Clinicians must understand the statistical and scientific limitations of the tests they are using, and appropriate ethical oversight is essential until such time that validated testing instruments are available that are performed in a standardized clinical testing environment. Well-controlled prospective studies are necessary to identify the most accurate, widely accessible, and affordable tests for routine clinical use.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Volume148
Issue number6
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Patient Care
Gene Expression Profiling
Cytogenetics
Prospective Studies
DNA
Uveal melanoma
Clinical Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Molecular Prognostic Testing and Individualized Patient Care in Uveal Melanoma. / William Harbour, J.

In: American Journal of Ophthalmology, Vol. 148, No. 6, 01.12.2009.

Research output: Contribution to journalArticle

@article{9da0087716c7418aab5a900571fecc6c,
title = "Molecular Prognostic Testing and Individualized Patient Care in Uveal Melanoma",
abstract = "Purpose: To critically assess the status of molecular prognostic testing and its use for individualized patient care in uveal melanoma. Design: Perspective, literature review, evidence assessment, and commentary. Methods: Evaluation of selected articles from the literature and the authors' clinical and laboratory studies. Results: The most accurate molecular tests for predicting metastatic death in patients with uveal melanoma currently involve automated techniques for assessing deoxyribonucleic acid (DNA) copy number alterations and gene expression profiling. Most tests reported in the literature to date do not provide adequate scientific and statistical validation to be used outside of an ethically supervised investigational environment. Conclusions: Many cytogenetic and molecular prognostic tests for uveal melanoma have been reported, yet few have reached the standards required for routine clinical testing. Clinicians must understand the statistical and scientific limitations of the tests they are using, and appropriate ethical oversight is essential until such time that validated testing instruments are available that are performed in a standardized clinical testing environment. Well-controlled prospective studies are necessary to identify the most accurate, widely accessible, and affordable tests for routine clinical use.",
author = "{William Harbour}, J.",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/j.ajo.2009.07.004",
language = "English",
volume = "148",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Molecular Prognostic Testing and Individualized Patient Care in Uveal Melanoma

AU - William Harbour, J.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Purpose: To critically assess the status of molecular prognostic testing and its use for individualized patient care in uveal melanoma. Design: Perspective, literature review, evidence assessment, and commentary. Methods: Evaluation of selected articles from the literature and the authors' clinical and laboratory studies. Results: The most accurate molecular tests for predicting metastatic death in patients with uveal melanoma currently involve automated techniques for assessing deoxyribonucleic acid (DNA) copy number alterations and gene expression profiling. Most tests reported in the literature to date do not provide adequate scientific and statistical validation to be used outside of an ethically supervised investigational environment. Conclusions: Many cytogenetic and molecular prognostic tests for uveal melanoma have been reported, yet few have reached the standards required for routine clinical testing. Clinicians must understand the statistical and scientific limitations of the tests they are using, and appropriate ethical oversight is essential until such time that validated testing instruments are available that are performed in a standardized clinical testing environment. Well-controlled prospective studies are necessary to identify the most accurate, widely accessible, and affordable tests for routine clinical use.

AB - Purpose: To critically assess the status of molecular prognostic testing and its use for individualized patient care in uveal melanoma. Design: Perspective, literature review, evidence assessment, and commentary. Methods: Evaluation of selected articles from the literature and the authors' clinical and laboratory studies. Results: The most accurate molecular tests for predicting metastatic death in patients with uveal melanoma currently involve automated techniques for assessing deoxyribonucleic acid (DNA) copy number alterations and gene expression profiling. Most tests reported in the literature to date do not provide adequate scientific and statistical validation to be used outside of an ethically supervised investigational environment. Conclusions: Many cytogenetic and molecular prognostic tests for uveal melanoma have been reported, yet few have reached the standards required for routine clinical testing. Clinicians must understand the statistical and scientific limitations of the tests they are using, and appropriate ethical oversight is essential until such time that validated testing instruments are available that are performed in a standardized clinical testing environment. Well-controlled prospective studies are necessary to identify the most accurate, widely accessible, and affordable tests for routine clinical use.

UR - http://www.scopus.com/inward/record.url?scp=70449685754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449685754&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2009.07.004

DO - 10.1016/j.ajo.2009.07.004

M3 - Article

C2 - 19800609

AN - SCOPUS:70449685754

VL - 148

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 6

ER -